Tag: Diabetes: Type II
Liraglutide Added to Capped Insulin Reduces Hemoglobin A1c
Liraglutide also significantly reduces mean body weight, daily insulin dose; increases quality of life
OCT1, SERT Genes Play Role in Metformin Intolerance
Intolerance up with low-expressing SERT S* alleles; multiplicative interaction for OCT1, SERT genotypes
Greater Drop in Hemoglobin A1c With Empagliflozin + Metformin
Greater reductions in HbA1c, weight compared to empagliflozin or metformin alone
Couple Phone Intervention Ups Glycemic Control for High A1C
No difference for phone (individual, couple), education interventions at highest A1C levels
Lipid Fractions May Be Linked to Risk of CAD, Diabetes
Increase in LDL-C, triglycerides linked to higher CAD risk; LDL-C, HDL-C linked to lower risk of diabetes
Pioglitazone Cuts Diabetes Risk After Ischemic Stroke, TIA
Findings for patients with recent ischemic stroke/TIA and insulin resistance, but no history of diabetes
Increased Risk of Diabetes With Nonfunctional Adrenal Tumors
Increased risk of incident composite diabetes compared to those without adrenal tumors
Mortality Up With Impaired Glucose Tolerance
Much of the increase associated with impaired glucose tolerance due to progression to diabetes
No Independent Link for Fatty Pancreas, T2DM
After adjustment for confounding variables, no significant correlation remains
SFRP4 Linked to Impaired Glucose Tolerance, T2DM
Higher levels of secreted frizzled-related protein 4 associated with impaired glucose tolerance, T2DM
